Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Management of Myeloma

Multiple Myeloma Imaging Strategies

Multiple Myeloma Epidemiology

Multiple Myeloma Treatment

Multiple Myeloma Symptoms

Multiple Myeloma Pathophysiology

Multiple Myeloma Diagnosis

Latest Multiple Myeloma News and Research

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

Rising bowel and ovarian cancer rates in younger adults raise new concerns

Cases of several cancers are rising in England among both younger and older adults, but rates of bowel and ovarian cancer are rising only among younger adults (under 50s), finds research published in the open access journal BMJ Oncology.

28 Apr 2026

New insights into predicting myeloma drug response

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma therapy.

28 Apr 2026

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold.

8 Apr 2026

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

8 Apr 2026

Machine learning helps predict risks during stem cell therapy for myeloma

Multiple myeloma is a cancer in which plasma cells, which normally produce antibodies, multiply uncontrollably in the bone marrow.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Study reveals genetic impact of Agent Orange on bone marrow cancers

More than 50 years after Agent Orange was used in Vietnam, a new national study published online ahead of print in Blood Advances highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes (MDS), a group of bone marrow cancers that can progress to acute leukemia.

23 Mar 2026

Rapid Novor receives Ontario Ministry of Health provisional license for EasyM® blood-based MRD test for multiple myeloma

Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, enabling the company to begin testing patients in Canada.

From Rapid Novor Inc 11 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy

The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies.

From Hanson Wade Group - 11th Innate Killer Summit 6 Feb 2026

Novel RNA molecule may influence patient survival in certain blood cancers

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus (a dense region of the cell containing a subset of crucial genetic material).

2 Feb 2026

Antibody-producing plasma cells shape effectiveness of PD-1 immunotherapy

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not.

27 Jan 2026

Study provides a new paradigm for managing transplant‑related immune complications

Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell transplantation (allo‑HSCT).

16 Jan 2026